SecBot SecBot
S-3 ·Filed Jul 17, 2026

AGEN

AGENUS INC
BEARISH
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-308110
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Monitor for any 424B prospectus supplement indicating an actual sale by Zynext. The 4.77% holder is underwater (~33% loss from purchase price), which increases the likelihood of eventual selling. The going-concern warning and heavy short interest (14.4%) amplify downside risk. Any material sale could pressure the stock further.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

AGEN drug pipeline →

botensilimab

◆ Mixed Named in this S-3
Impact
Phase
Phase 3
Time to market
At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
Next catalyst
None dated

What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.97
T+0 close · Jul 17, 2026 · via day close
Latest settled
+39.84%
T+60 · $6.95
Vs SPY
+35.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $4.97entry
  2. T+1 · 4mo ago +12.27%α +11.44% · $5.58
  3. T+5 · 4mo ago +20.32%α +20.75% · $5.98
  4. T+20 · 3mo ago +43.86%α +39.74% · $7.15
  5. T+60 · 5w ago +39.84%α +35.00% · $6.95

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Agenus filed an S-3 registration statement to register 2,133,333 shares of common stock for resale by Zynext Ventures USA LLC, a strategic investor that purchased these shares for ~$16.0M ($7.50/share) in a January 2026 private placement. This is a contractual registration obligation, not a new primary offering, Agenus receives no proceeds. The filing itself is neutral, but the context of a clinical-stage biotech with a going-concern audit opinion, $35M cash, and a $2.14B accumulated deficit makes the potential overhang from a 4.77% holder's resale a modest negative signal, especially given the stock's decline from the $7.50 purchase price to $5.00.

Key Facts

  • S-3 registers 2,133,333 shares for resale by Zynext Ventures USA LLC, representing 4.77% of shares outstanding as of July 17, 2026.
  • Shares were originally sold at $7.50/share for ~$16.0M in a January 2026 private placement; current market price is $5.00 (July 16, 2026).
  • Agenus receives no proceeds from this resale registration, it is a contractual obligation under the Securities Purchase Agreement.
  • Audit report for FY2025 contains a going-concern explanatory paragraph; accumulated deficit was $2.14B as of March 31, 2026.
  • Cash and cash equivalents were $35.0M as of March 31, 2026, up from $3.0M at year-end 2025, but the company is pre-revenue and burning cash.
  • Short interest is ~14.4% of estimated shares outstanding as of June 30, 2026.

Financial Impact

Potential overhang of ~$10.6M at current market prices from a 4.77% holder with a below-cost basis ($5.00 vs $7.50), creating incentive to sell.

dilutionstock price

Risk Factors

  • Zynext Ventures may sell shares at a loss, creating persistent overhang.
  • Going-concern uncertainty and $2.14B accumulated deficit raise financing risk.
  • High short interest (14.4%) could amplify any negative price movement.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-308110
Document: d125465dexfilingfees.htm0001193125-26-308110
Document: d125465dex51.htm0001193125-26-308110
Document: d125465dex232.htm0001193125-26-308110
Document: 0001193125-26-308110-index-headers.html0001193125-26-308110
Document: 0001193125-26-308110-index.html0001193125-26-308110
Document: 0001193125-26-308110.txt0001193125-26-308110

Track record

12 reports on AGEN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
  4. Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
  6. Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
  7. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
  8. Jul 17, 202617w ago S-3 Bearish 5/10 Viewing Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
  9. Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
  10. May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026